HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.
-
- STATUS
- Recruiting
-
- participants needed
- 180
-
- sponsor
- SOLTI Breast Cancer Research Group
Summary
This is a multi-center, observational study. Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent.
In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these patients.
Description
This is a multi-center, observational study. Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent.
After signing the informed consent form:
- For patients who have already begun dosing in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials, an archival metastatic biopsy will be requested for inclusion purposes.
- For patients who have not yet dosed in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials eligible patients will undergo a fresh biopsy of a metastatic site. If not feasible, archival sample from metastatic site will be accepted. Blood samples will be collected from eligible patients for biomarker analyses.
In both cases, a breast tumor sample will be acceptable for those patients who are diagnosed with de novo metastatic breast cancer.
Exceptionally, for those patients who do not have a metastatic sample or the possibility of obtaining it in the cases mentioned above, the possibility of sending a sample of the primary tumor for inclusion purposes may be requested. SOLTI will confirm if the patient can be included.
In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these patients.
Details
| Condition | Metastatic Breast Cancer |
|---|---|
| Age | 18-100 years |
| Treatment | Tumor and Blood sample collection |
| Clinical Study Identifier | NCT04257162 |
| Sponsor | SOLTI Breast Cancer Research Group |
| Last Modified on | 19 February 2024 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Add a private note
- Select a piece of text from the left.
- Add notes visible only to you.
- Send it to people through a passcode protected link.
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.